INTANGIBLE ASSETS AND GOODWILL

Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2018. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.



(Dollars in Millions)	March 31, 2019		December 30, 2018
Intangible assets with definite lives:
Patents and trademarks — gross	$	35,963	35,194
Less accumulated amortization	10,548		9,784
Patents and trademarks — net	25,415		25,410
Customer relationships and other intangibles — gross	21,766		21,334
Less accumulated amortization	8,586		8,323
Customer relationships and other intangibles — net	13,180		13,011
Intangible assets with indefinite lives:
Trademarks	6,912		6,937
Purchased in-process research and development ⁽¹⁾	1,391		2,253
Total intangible assets with indefinite lives	8,303		9,190
Total intangible assets — net	$	46,898	47,611

⁽¹⁾In the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter of 2018 related to the development program of AL-8176.

Goodwill as of March 31, 2019 was allocated by segment of business as follows:



(Dollars in Millions)	Consumer			Pharm		Med Devices		Total
Goodwill, net at December 30, 2018	$	8,670		9,063		12,720		30,453
Goodwill, related to acquisitions	1,176			—		23		1,199
Goodwill, related to divestitures	—			—		—		—
Currency translation/Other	(116		)	(75	)	(11	)	(202	)
Goodwill, net at March 31, 2019	$	9,730		8,988		12,732		31,450

Goodwill is net of approximately $0.3 billion related to the divestiture of the Advanced Sterilization Products business, which was pending and classified as assets held for sale on the Consolidated Balance Sheet as of March 31, 2019.

The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion and $1.1 billion for the fiscal first quarters ended ended March 31, 2019 and April 1, 2018, respectively. The estimated amortization expense for the five succeeding years approximates $4.4 billion, before tax, per year. Intangible asset write-downs, other than in-process research and development are included in Other (income) expense, net.

See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.